[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100521834":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":31,"centralContacts":36,"locations":46,"responsibleParty":72,"collaborators":40,"id":75,"slug":40,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":40,"eligibilityCriteria":80,"healthyVolunteers":76,"sex":81,"minAge":82,"maxAge":40,"enrollmentInfo":83,"targetDuration":40,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":48,"whyStopped":40,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Luzerner Kantonsspital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention group: SSNB + IPACK (group 1)","ACTIVE_COMPARATOR","Subsartorial Nerve Block:\n\n* 15ml bupivacaine 0.5% + clonidine 1mcg\u002Fkg for prolongation of the block effect\n* anatomic landmarks: proximal adductor channel, intersection of the medial borders of the sartorius muscle and the adductor longus, guided by ultrasound control\n* no patch to puncture site to not jeopardise the surgeon's blinding\n* IPACK: 15ml bupivacaine 0.5% after completion of the femoral preparation",[13],"Other: SSNB + IPACK",{"label":15,"type":10,"description":16,"interventionNames":17},"Control group: FNB + IPACK (group 2)","Femoral Nerve Block:\n\n* 15ml bupivacaine 0.5% + clonidine 1mcg\u002Fkg for prolongation of the block effect\n* anatomic landmarks: lateral to the femoral artery,level of the femoral crease (proximal to the vascular outlet of the deep artery of the thigh), femoral nerve lies on the surface of the iliopsoas muscle and is covered by the fascia iliaca, guided by ultrasound control\n* no patch to puncture site to not jeopardise the surgeon's blinding\n* IPACK: 15ml bupivacaine 0.5% after completion of the femoral preparation",[18],"Other: FNB + IPACK",[20,26],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"SSNB + IPACK","already included in arm\u002Fgroup description",[9],[25],"Subsartorial Nerve Block",{"type":6,"name":27,"description":22,"armGroupLabels":28,"otherNames":29},"FNB + IPACK",[15],[30],"Femoral Nerve Block",[32],{"name":33,"affiliation":34,"role":35},"Judith Bering, Dr. med.","Luzerner Kantonsspital Luzern","PRINCIPAL_INVESTIGATOR",[37,42],{"name":33,"role":38,"phone":39,"phoneExt":40,"email":41},"CONTACT","+41 41 205 18 91",null,"judith.bering@luks.ch",{"name":43,"role":38,"phone":44,"phoneExt":40,"email":45},"Laura V Buchmann, Dr. med.","0041-41-2057855","laura.buchmann@luks.ch",[47],{"facility":5,"status":48,"city":49,"state":40,"zip":50,"country":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"RECRUITING","Lucerne","6000","Switzerland",{"type":53,"coordinates":54},"Point",[55,56],8.30635,47.05048,{"lat":56,"lon":55},[59,61,63,64,67,69,70],{"name":33,"role":38,"phone":60,"phoneExt":40,"email":41},"+41-41-2051891",{"name":43,"role":38,"phone":62,"phoneExt":40,"email":45},"+41-41-2057855",{"name":33,"role":35,"phone":40,"phoneExt":40,"email":40},{"name":65,"role":66,"phone":40,"phoneExt":40,"email":40},"Urs W Müller, Prof. PH","SUB_INVESTIGATOR",{"name":68,"role":66,"phone":40,"phoneExt":40,"email":40},"Flavio Cagienard, Dr. med.",{"name":43,"role":66,"phone":40,"phoneExt":40,"email":40},{"name":71,"role":66,"phone":40,"phoneExt":40,"email":40},"Tobias Ulmer, Dr. med.",{"type":35,"investigatorFullName":73,"investigatorTitle":74,"investigatorAffiliation":5,"oldNameTitle":40,"oldOrganization":40},"Judith Bering","Principal Investigator","100521834",false,"NCT06074744","Subsartorial Nerve Block and Femoral Nerve Block in Total Knee Arthroplasty","Subsartorial Saphenous Nerve Block (SSNB) Versus Femoral Nerve Block (FNB) in Primary Total Knee Arthroplasty (TKA) Combined With Infiltration Between Popliteal Artery and Capsule of the Knee (IPACK) - Where Are the Benefits?","Inclusion criteria:\n\n* age \\> 18yrs\n* primary TKA\n* BMI 35kg\u002Fm2 or less\n* able to give informed consent as documented by signature\n* clinical history without any contraindications for the planned intervention\n\nExclusion criteria:\n\n* age \\\u003C 18 years\n* revision-TKA\n* BMI \\>35kg\u002Fm2\n* absent contact information\n* inability or contraindications to undergo the investigated intervention (TKA, FNB, SSNB), - clinically significant concomitant diseases\n* pregnancy\n* inability to follow the procedures and follow-up procedures of the study (e.g. due to language problems, psychological disorders, dementia, living abroad, etc.\n* withdrawal from the study","ALL","18 Years",{"count":84,"type":85},144,"ESTIMATED","INTERVENTIONAL",[88],"NA","The goal of this clinical trial is to compare two different types of nerve blocks in patients undergoing surgery for primary Total Knee Arthroplasty. The main question aim to answer is:\n\n\\- is there a benefit in functional muscle power output of the leg?\n\nParticipants will be randomized into either the intervention group or the control group and:\n\n* receive Subsartorial Saphenous Nerve Block (SSNB) + IPACK in intervention group (group 1)\n* receive Femoral Nerve Block (FNB) + IPACK in control group (group 2)\n\nResearchers will compare the 2 groups to see if there are differences in :\n\n* functional muscle power output of the leg?\n* muscle function, mobility, clinical and radiological results, ROM, pain control (NRS), opioid consumption, length of hospital stay, patient satisfaction, mobility, reduction of costs?",[91,92],"Joint Diseases","Joint Pain",[94,95,96],"Subsartorial Saphenous Nerve Block (SSNB)","Femoral Nerve Block (FNB)","Total Knee Arthroplasty (TKA)","2024-03-07",{"date":99,"type":100},"2024-03-12","ACTUAL",{"date":102,"type":100},"2023-11-30",{"date":104,"type":85},"2026-12",{"name":5,"class":6},1]